The HEDIMED project, funded by the EU, invites stakeholders including researchers, healthcare professionals, and policymakers to its final event. Since its launch in 2020, HEDIMED has focused on the exposome’s impact on immune-mediated diseases such as asthma, allergies, celiac disease, and type 1 diabetes.

The event will share key findings, innovative technologies for exposome research, and policy insights. Participants are encouraged to join online for a day of learning and discussion about the exposome’s role in public health.

More information at: HEDIMED